Dermira Company Profile (NASDAQ:DERM)

About Dermira (NASDAQ:DERM)

Dermira logoDermira, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor, or TNF inhibitor that is approved and marketed for the treatment of numerous inflammatory diseases spanning multiple medical specialties, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease, in multiple countries, including the United States. Glycopyrronium tosylate is a small molecule anticholinergic product for topical application for the treatment of primary axillary hyperhidrosis. Olumacostat glasaretil is a small molecule that targets sebum production following topical application for the treatment of acne.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:DERM
  • CUSIP: N/A
  • Web:
  • Market Cap: $1.17329 billion
  • Outstanding Shares: 41,591,000
Average Prices:
  • 50 Day Moving Avg: $26.17
  • 200 Day Moving Avg: $28.34
  • 52 Week Range: $21.35 - $38.75
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.85
  • P/E Growth: -0.06
Sales & Book Value:
  • Annual Revenue: $24.72 million
  • Price / Sales: 46.86
  • Book Value: $8.95 per share
  • Price / Book: 3.11
  • EBITDA: ($102,210,000.00)
  • Net Margins: -408.50%
  • Return on Equity: -31.66%
  • Return on Assets: -22.59%
  • Debt-to-Equity Ratio: 0.75%
  • Current Ratio: 24.43%
  • Quick Ratio: 24.43%
  • Average Volume: 414,823 shs.
  • Beta: 0.88
  • Short Ratio: 16.84

Frequently Asked Questions for Dermira (NASDAQ:DERM)

What is Dermira's stock symbol?

Dermira trades on the NASDAQ under the ticker symbol "DERM."

How were Dermira's earnings last quarter?

Dermira, Inc. (NASDAQ:DERM) announced its quarterly earnings results on Monday, August, 7th. The company reported ($0.93) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.89) by $0.04. The business earned $1.07 million during the quarter, compared to analyst estimates of $1 million. Dermira had a negative net margin of 408.50% and a negative return on equity of 31.66%. View Dermira's Earnings History.

Where is Dermira's stock going? Where will Dermira's stock price be in 2017?

8 brokers have issued 12 month price targets for Dermira's shares. Their forecasts range from $40.00 to $48.00. On average, they expect Dermira's stock price to reach $44.40 in the next year. View Analyst Ratings for Dermira.

What are analysts saying about Dermira stock?

Here are some recent quotes from research analysts about Dermira stock:

  • 1. According to Zacks Investment Research, "Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. " (8/17/2017)
  • 2. Guggenheim analysts commented, "4Q16 results underscore that DERM continues to advance its pipeline of drugs that address large unmet needs in dermatology. Positive clinical data for DRM01 and DRM04 as well as solid execution in 4Q16, give us greater conviction in our positive investment thesis for the stock. We continue to think stock price appreciation will be driven by upward consensus earnings revisions to DERM's pipeline drug sales. We also view DERM as an attractive company in a consolidating industry." (3/2/2017)

Who are some of Dermira's key competitors?

Who are Dermira's key executives?

Dermira's management team includes the folowing people:

  • Thomas G. Wiggans, Chairman of the Board, Chief Executive Officer, Co-Founder
  • Christopher M. Griffith, Senior Vice President - Corporate Development and Strategy, Founder
  • Luis C. Pena, Co-Founder, Chief Development Officer
  • Andrew L. Guggenhime, Chief Financial Officer, Chief Operating Officer
  • Lori Lyons-Williams, Chief Commercial Officer
  • Eugene A. Bauer M.D., Founder, Chief Medical Officer, Director
  • Frederick B. Craves Ph.D., Lead Independent Director
  • Emmanuel Caeymaex, Director
  • David E. Cohen M.D., Independent Director
  • Matthew K. Fust, Independent Director

How do I buy Dermira stock?

Shares of Dermira can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dermira's stock price today?

One share of Dermira stock can currently be purchased for approximately $27.85.

MarketBeat Community Rating for Dermira (NASDAQ DERM)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  141 (Vote Outperform)
Underperform Votes:  105 (Vote Underperform)
Total Votes:  246
MarketBeat's community ratings are surveys of what our community members think about Dermira and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Dermira (NASDAQ:DERM) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Sell Ratings, 5 Buy Ratings
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: $44.40 (59.43% upside)
Consensus Price Target History for Dermira (NASDAQ:DERM)
Price Target History for Dermira (NASDAQ:DERM)
Analysts' Ratings History for Dermira (NASDAQ:DERM)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/26/2017Cantor FitzgeraldReiterated RatingBuy$45.00LowView Rating Details
9/17/2017Needham & Company LLCReiterated RatingBuy$46.00HighView Rating Details
9/7/2017MizuhoReiterated RatingBuy$40.00 -> $43.00LowView Rating Details
6/29/2017Evercore ISIInitiated CoverageOutperform$48.00MediumView Rating Details
3/16/2017Raymond James Financial, Inc.Initiated CoverageUnderperform -> UnderperformHighView Rating Details
3/15/2017Citigroup Inc.Initiated CoverageUnderperformHighView Rating Details
3/2/2017GuggenheimReiterated RatingBuy -> Positive$40.00N/AView Rating Details
1/3/2017SEB Equity ResearchReiterated RatingReduceN/AView Rating Details
10/5/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
6/2/2016WedbushBoost Price TargetOutperform$42.00 -> $46.00N/AView Rating Details
(Data available from 10/18/2015 forward)


Earnings History for Dermira (NASDAQ:DERM)
Earnings by Quarter for Dermira (NASDAQ:DERM)
Earnings History by Quarter for Dermira (NASDAQ DERM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2017Q2 2017($0.89)($0.93)$1.00 million$1.07 millionViewN/AView Earnings Details
2/28/2017Q4 2016($0.93)($0.21)$22.47 millionViewListenView Earnings Details
11/7/2016Q316($0.72)($0.72)$0.12 millionViewN/AView Earnings Details
8/8/2016Q2($0.86)($0.89)ViewN/AView Earnings Details
5/10/2016Q1($0.94)($0.95)ViewListenView Earnings Details
11/10/2015Q3($0.77)($0.58)$7.30 millionViewN/AView Earnings Details
8/13/2015Q2($0.81)($0.69)ViewN/AView Earnings Details
5/12/2015Q1($0.65)($0.57)ViewN/AView Earnings Details
3/25/2015Q4($0.59)($0.29)$7.30 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Dermira (NASDAQ:DERM)
2017 EPS Consensus Estimate: ($3.97)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.84)($0.84)($0.84)
Q2 20171($0.81)($0.81)($0.81)
Q3 20171($1.03)($1.03)($1.03)
Q4 20171($1.29)($1.29)($1.29)
(Data provided by Zacks Investment Research)


Dividend History for Dermira (NASDAQ:DERM)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Dermira (NASDAQ:DERM)
Insider Ownership Percentage: 13.30%
Institutional Ownership Percentage: 97.56%
Insider Trades by Quarter for Dermira (NASDAQ:DERM)
Institutional Ownership by Quarter for Dermira (NASDAQ:DERM)
Insider Trades by Quarter for Dermira (NASDAQ:DERM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/11/2017Eugene A BauerInsiderSell7,500$30.04$225,300.00View SEC Filing  
10/10/2017Thomas G WiggansCEOSell5,000$27.52$137,600.00View SEC Filing  
10/2/2017David E CohenDirectorSell600$26.99$16,194.00View SEC Filing  
9/18/2017Thomas G. WiggansCEOSell9,500$27.51$261,345.00View SEC Filing  
9/1/2017David E CohenDirectorSell600$23.56$14,136.00View SEC Filing  
8/28/2017David E CohenDirectorSell600$23.81$14,286.00View SEC Filing  
8/14/2017Fred B CravesDirectorBuy30,000$23.03$690,900.00View SEC Filing  
8/1/2017Thomas G. WiggansCEOSell500$27.58$13,790.00View SEC Filing  
7/5/2017Eugene A BauerInsiderSell2,500$30.00$75,000.00View SEC Filing  
7/3/2017Thomas G. WiggansCEOSell5,000$29.06$145,300.00View SEC Filing  
6/20/2017Eugene A BauerInsiderSell2,500$30.01$75,025.00View SEC Filing  
6/2/2017Thomas G. WiggansCEOSell5,000$27.52$137,600.00View SEC Filing  
5/15/2017Christopher M. GriffithSVPSell1,312$27.07$35,515.84View SEC Filing  
4/17/2017Christopher M. GriffithSVPSell1,303$33.97$44,262.91View SEC Filing  
4/3/2017Eugene A BauerInsiderSell2,500$33.53$83,825.00View SEC Filing  
4/3/2017Thomas G WiggansCEOSell8,000$33.49$267,920.00View SEC Filing  
4/3/2017William R RingoDirectorSell500$34.03$17,015.00View SEC Filing  
3/15/2017Christopher M. GriffithSVPSell1,303$35.79$46,634.37View SEC Filing  
3/1/2017Eugene A BauerInsiderSell2,500$33.61$84,025.00View SEC Filing  
3/1/2017Thomas G WiggansCEOSell11,000$33.54$368,940.00View SEC Filing  
3/1/2017William R RingoDirectorSell500$35.09$17,545.00View SEC Filing  
2/15/2017Christopher M. GriffithSVPSell1,303$30.79$40,119.37View SEC Filing  
2/15/2017William R RingoDirectorSell500$32.00$16,000.00View SEC Filing  
2/14/2017Eugene A BauerInsiderSell1,505$30.00$45,150.00View SEC Filing  
2/1/2017Eugene A BauerInsiderSell995$30.00$29,850.00View SEC Filing  
1/17/2017Christopher M. GriffithVPSell1,303$29.11$37,930.33View SEC Filing  
1/4/2017Thomas G WiggansCEOSell8,000$31.06$248,480.00View SEC Filing  
1/4/2017William R RingoDirectorSell500$32.00$16,000.00View SEC Filing  
1/3/2017Eugene A BauerInsiderSell2,500$30.07$75,175.00View SEC Filing  
12/16/2016William R RingoDirectorSell125$32.00$4,000.00View SEC Filing  
12/15/2016Christopher M. GriffithVPSell1,303$30.70$40,002.10View SEC Filing  
12/14/2016Eugene A BauerInsiderSell2,500$30.36$75,900.00View SEC Filing  
12/1/2016Thomas G WiggansCEOSell11,000$30.80$338,800.00View SEC Filing  
12/1/2016William R RingoDirectorSell375$32.00$12,000.00View SEC Filing  
11/9/2016Andrew GuggenhimeCFOSell4,100$35.02$143,582.00View SEC Filing  
11/9/2016William R RingoDirectorSell500$32.30$16,150.00View SEC Filing  
11/1/2016Thomas G WiggansCEOSell11,000$31.19$343,090.00View SEC Filing  
10/17/2016Christopher M GriffithVPSell1,303$32.33$42,125.99View SEC Filing  
10/11/2016Andrew GuggenhimeCFOSell10,900$34.34$374,306.00View SEC Filing  
10/3/2016Thomas G WiggansCEOSell11,000$34.60$380,600.00View SEC Filing  
10/3/2016William R RingoDirectorSell500$34.25$17,125.00View SEC Filing  
9/19/2016Andrew GuggenhimeCFOSell15,000$35.01$525,150.00View SEC Filing  
9/15/2016Christopher M GriffithVPSell1,303$33.26$43,337.78View SEC Filing  
9/12/2016Andrew GuggenhimeCFOSell10,000$32.53$325,300.00View SEC Filing  
9/1/2016Thomas G WiggansCEOSell11,000$31.63$347,930.00View SEC Filing  
9/1/2016William R RingoDirectorSell500$32.00$16,000.00View SEC Filing  
8/15/2016Christopher M GriffithVPSell1,303$31.75$41,370.25View SEC Filing  
8/11/2016Andrew GuggenhimeCFOSell10,000$31.02$310,200.00View SEC Filing  
8/1/2016Eugene A BauerInsiderSell2,500$33.18$82,950.00View SEC Filing  
8/1/2016Thomas G WiggansCEOSell11,000$33.19$365,090.00View SEC Filing  
8/1/2016William R RingoDirectorSell500$33.65$16,825.00View SEC Filing  
7/15/2016Christopher M GriffithVPSell1,303$30.02$39,116.06View SEC Filing  
7/11/2016Andrew GuggenhimeCFOSell10,000$30.15$301,500.00View SEC Filing  
7/5/2016Thomas G WiggansCEOSell11,000$29.62$325,820.00View SEC Filing  
7/1/2016Eugene A BauerInsiderSell2,500$29.48$73,700.00View SEC Filing  
6/23/2016Luis C PenaInsiderSell10,000$30.01$300,100.00View SEC Filing  
6/15/2016Luis C PenaInsiderSell10,000$29.47$294,700.00View SEC Filing  
6/13/2016Christopher M GriffithVPSell4,405$30.16$132,854.80View SEC Filing  
6/1/2016Eugene A BauerInsiderSell2,500$31.65$79,125.00View SEC Filing  
6/1/2016Thomas G WiggansCEOSell11,000$31.57$347,270.00View SEC Filing  
5/2/2016Eugene A BauerInsiderSell2,500$25.09$62,725.00View SEC Filing  
5/2/2016Thomas G WiggansCEOSell9,000$25.11$225,990.00View SEC Filing  
4/1/2016Eugene A BauerInsiderSell2,500$20.84$52,100.00View SEC Filing  
4/1/2016Thomas G WiggansCEOSell7,000$20.69$144,830.00View SEC Filing  
3/1/2016Eugene A BauerInsiderSell2,500$22.55$56,375.00View SEC Filing  
3/1/2016Thomas G WiggansCEOSell7,000$22.57$157,990.00View SEC Filing  
2/1/2016Eugene A BauerInsiderSell2,500$27.26$68,150.00View SEC Filing  
2/1/2016Thomas G WiggansCEOSell9,000$27.25$245,250.00View SEC Filing  
1/4/2016Eugene A BauerInsiderSell2,500$33.17$82,925.00View SEC Filing  
1/4/2016Thomas G WiggansCEOSell11,000$33.17$364,870.00View SEC Filing  
12/1/2015Eugene A BauerInsiderSell2,500$29.65$74,125.00View SEC Filing  
11/2/2015Eugene A BauerInsiderSell2,500$27.82$69,550.00View SEC Filing  
10/1/2015Eugene A BauerInsiderSell2,500$22.87$57,175.00View SEC Filing  
9/14/2015Eugene A BauerInsiderSell22,500$28.05$631,125.00View SEC Filing  
11/25/2014Matthew K FustDirectorBuy6,000$16.77$100,620.00View SEC Filing  
10/8/2014Bay City Capital LlcDirectorBuy69,112$16.00$1,105,792.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Dermira (NASDAQ:DERM)
Latest Headlines for Dermira (NASDAQ:DERM)
DateHeadline logo Analysts Anticipate Dermira, Inc. (DERM) to Post -$1.12 EPS - October 17 at 8:24 PM logoCorporate News Blog - Dermira Highlights Results from ARIDO Study for Assessment of Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis Patients - October 16 at 6:34 PM logoDermira (DERM) Announces New Long-Term Safety Data for Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis - October 14 at 5:39 PM logoDermira Highlights New Long-Term Safety Data for Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis at Fall Clinical Dermatology Conference - October 13 at 6:22 PM logoEugene A. Bauer Sells 7,500 Shares of Dermira, Inc. (DERM) Stock - October 13 at 1:34 PM logoInsider Selling: Dermira, Inc. (DERM) CEO Sells 5,000 Shares of Stock - October 11 at 10:34 PM logoDermira (DERM) Shares Cross Above 200 DMA - October 11 at 7:21 PM logoDermira, Inc. (DERM) Soars: Stock Adds 5.3% in Session - October 11 at 7:21 PM logoSurprising Analyst 12-Month Target For IHE - October 9 at 6:13 PM logoDermira Completes Patient Enrollment in Two Phase 3 Pivotal Trials of Olumacostat Glasaretil for the Treatment of Acne Vulgaris - October 5 at 10:29 AM logoDavid E. Cohen Sells 600 Shares of Dermira, Inc. (DERM) Stock - October 3 at 11:56 PM logoDermira, Inc. (DERM) Expected to Announce Quarterly Sales of $1.05 Million - October 1 at 1:02 PM logoDermira, Inc. (DERM) Given Consensus Rating of "Hold" by Analysts - September 30 at 1:04 PM logo-$1.12 EPS Expected for Dermira, Inc. (DERM) This Quarter - September 29 at 4:28 AM logoCantor Fitzgerald Reaffirms "Buy" Rating for Dermira, Inc. (DERM) - September 27 at 6:10 PM logoCommit To Buy Dermira At $17.50, Earn 29.6% Annualized Using Options - September 22 at 10:14 PM logoDermira to Present at Cantor Fitzgerald Global Healthcare Conference - September 20 at 6:39 PM logoThomas G. Wiggans Sells 9,500 Shares of Dermira, Inc. (DERM) Stock - September 19 at 7:42 PM logoDermira, Inc. – Value Analysis (NASDAQ:DERM) : September 19, 2017 - September 18 at 10:51 PM logoDermira, Inc. (DERM) Stock Rating Reaffirmed by Needham & Company LLC - September 17 at 8:58 AM logoDermira, Inc. breached its 50 day moving average in a Bullish Manner : DERM-US : September 15, 2017 - September 15 at 6:20 PM logoBRIEF-New CIMZIA findings presented at European Academy Of Dermatology And Venereology (EADV) Congress - September 14 at 11:45 PM logoNew CIMZIA® (certolizumab pegol) Findings Presented at European Academy of Dermatology and Venereology (EADV) Congress - September 14 at 6:44 PM logoDermira Announces Early Termination of the Hart-Scott-Rodino Waiting Period for License to Lebrikizumab - September 14 at 6:44 PM logoDermira (DERM) Announces Data Showing Impact of Primary Axillary Hyperhidrosis on Patients - September 13 at 7:10 PM logoDermira Presents New Data Showing Impact of Primary Axillary Hyperhidrosis on Patients - September 13 at 7:10 PM logoIs It The Right Time To Buy Dermira Inc (DERM)? - September 8 at 11:12 PM logoDermira (DERM) Reports New Data on Late-Stage Programs at Leading European Dermatology Congress - September 8 at 6:11 PM logoDermira, Inc. (DERM) Earns Buy Rating from Mizuho - September 7 at 10:08 PM logoDermira Presents New Data on Late-Stage Programs at Leading European Dermatology Congress - September 7 at 5:54 PM logoDermira, Inc. (DERM) Director David E. Cohen Sells 600 Shares - September 5 at 8:52 PM logoDermira, Inc. (DERM) Given Average Recommendation of "Hold" by Analysts - September 5 at 12:32 PM logo Analysts Expect Dermira, Inc. (DERM) Will Post Earnings of -$1.12 Per Share - August 22 at 8:26 PM logoDermira, Inc. (DERM) Director Fred B. Craves Buys 30,000 Shares - August 14 at 10:46 PM logoSee what the IHS Markit Score report has to say about Dermira Inc. - August 14 at 6:11 PM logoDermira, Inc. (NASDAQ:DERM) Receives Average Rating of "Hold" from Brokerages - August 11 at 6:18 PM logoIs Dermira Inc (NASDAQ:DERM)'s Confidence In Lebrikizumab Warranted? - August 11 at 12:07 AM logoLeerink Swann Comments on Dermira, Inc.'s Q3 2017 Earnings (NASDAQ:DERM) - August 10 at 12:04 PM logoDermira (DERM) Enters Pact to License Exclusive, Worldwide Rights to Lebrikizumab - August 9 at 5:58 PM
News IconBRIEF-Dermira enters into agreement to license exclusive, worldwide rights to Lebrikizumab - August 9 at 5:58 PM logoEquities Analysts Offer Predictions for Dermira, Inc.'s FY2020 Earnings (DERM) - August 9 at 3:02 PM logoDermira Enters into Agreement to License Exclusive, Worldwide Rights to Lebrikizumab - August 8 at 5:32 PM logoDermira, Inc. (DERM) Releases Quarterly Earnings Results - August 8 at 12:46 PM logoDermira Becomes Oversold (DERM) - August 7 at 6:12 PM logoBRIEF-Dermira Q2 qtrly ‍net loss per share $0.93 - August 7 at 6:12 PM logoDermira Reports Second Quarter 2017 Financial Results and Provides Corporate Update - August 7 at 6:12 PM logoDermira reports 2Q loss - August 7 at 6:12 PM logoDermira, Inc. (NASDAQ:DERM) CEO Sells $13,790.00 in Stock - August 2 at 9:38 PM logoSuffering from excessive perspiration? Don't sweat it, we... - July 28 at 7:51 PM logoUCB and Dermira Announce U.S. and EU Regulatory... - July 25 at 5:49 PM



Dermira (DERM) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.